<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914186</url>
  </required_header>
  <id_info>
    <org_study_id>TS022-US201</org_study_id>
    <nct_id>NCT00914186</nct_id>
  </id_info>
  <brief_title>Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adult Patients With a Diagnosis of Atopic Dermatitis (AD) With Moderate to Very Severe Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and
      tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe
      pruritus (itching), following a 28-day regimen of twice-daily topical application.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (none provided)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pruritis Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
    <description>Patient reported outcome of pruritis measurement (0-100 mm/min-max)on a change in visual analog scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of TS-022 Topical Lotion as Measured by Participants Who Demonstrated Adverse Events</measure>
    <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
    <description>Safety assessment of all subjects who received investigational product. Outcome measure is number of subjects with an adverse event. Measures of adverse events in participants included vital signs, laboratory findings, physical exams, electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) Based on a Dermatologist's Evalution of the Change in Subject's Score of Target Treatment Areas</measure>
    <time_frame>baseline through Study Day 36 (Visit 7)</time_frame>
    <description>investigator assessment of disease status rated on 0-5 scale (0 = clear to 5 = very severe) based on a change in score from baseline to Study Day 36 (Visit 7)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Five Point Pruritus Scale for Self-Assessment of Target Treatment Area Based on a Change in Score</measure>
    <time_frame>Baseline, which is Day -7 (Visit 2), through Day 36 (Visit 7)</time_frame>
    <description>self-assessment using a five point scale of pruritus state based on a change in scale from none (0) to very severe (4), interfering with daily or sleep activities. Subjects will complete the Five-Point Pruritus Scale once at Screening (Visit 1), then twice daily beginning at baseline, which occurs on the morning of Study Day -7 (Visit 2), through Study Day 36 (Visit 7)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI) Based on a Change in Score of Eruption in Proportionate Body Surface Areas</measure>
    <time_frame>baseline through Study Day 36 (Visit 7)</time_frame>
    <description>The head and neck [10%], trunk [30%], upper extremities [20%] and lower extremities [40%] were assessed separately for erythema (E), infiltration/papulation (I), excoriation (Ex) and lichenification (L) represented by a numeric coded value of (0, No eruption) to (6, 90% - 100% eruption). One score given to each part of the body on a scale from 1-6 based on the four attributes (E, I, Ex, L) and then a proportional average is taken to get a total score of 1-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skindex-29 Questionnaire to Measure the Subject's Overall Quality of Life Based on Activities of Daily Living That Affect Change in Emotion (10 to 50 Points), Symptoms (7 to 35 Points) and Functioning (12 to 60 Points) to Skin Over One Week Period.</measure>
    <time_frame>Study Day -7 through Study Day 22</time_frame>
    <description>Assessment of subject's activities of daily living using the SKINDEX-29 questionnaire to measure the subject's overall quality of life based on a change in scale from baseline. The SKINDEX scoring scale has a range of 29-145. The smaller the number the better the patient feels. The results are the difference of the SKINDEX scoring scale at treatment discharge (day 22) minus baseline (day-7). Hence the results should be negative, as the patient's emotion, symptoms and functioning of the skin should feel better at treatment discharge as opposed to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Measurable Pruritis Based on a Visual Horizontal Analog Scale</measure>
    <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
    <description>Pruritis Visual Analog Scale (VAS) based on patient reported outcome of pruritis measurement on a VAS indicating the amount of pruritus (itchiness) experienced from the time of last dose application through the time just before current dose application. Change in pruritus is assessed twice daily beginning at baseline, Study Day -7 (Visit 2), through Study Day 36 (Visit 7). Subjects determine measurable pruritis using a visual horizontal analog scale ranging from &quot;No Itch&quot;, even the slightest itch or &quot;Slight Itch&quot;, to &quot;Worst Itch Imaginable&quot; to denote the increase in severity of itching.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-022 0.005% lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-022 0.010% lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-022 0.020% lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS022</intervention_name>
    <description>Lotion</description>
    <arm_group_label>TS-022 0.005% lotion</arm_group_label>
    <arm_group_label>TS-022 0.010% lotion</arm_group_label>
    <arm_group_label>TS-022 0.020% lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Lotion</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults, males or females, 18 - 65 years of age at the time of obtaining the written
             Informed Consent

          2. Generally healthy subjects, who have no past or present history of any significant
             and/or newly-diagnosed disease or condition

          3. A score of 2 (Mild Disease), 3 (Moderate Disease) or 4 (Severe Disease) on the
             Investigator's Global Assessment of Atopic Dermatitis (IGA) Scale

          4. A score of 2 (Moderate Pruritus), 3 (Severe Pruritus) or 4 (Very Severe Pruritus) on
             the Five-Point Pruritus Scale

          5. Patient satisfies the diagnostic criteria for AD as determined by the criteria of
             Hanifin and Rajka

          6. Patient understands the study procedures and agrees to participate in the study by
             giving written Informed Consent

          7. Ability to read and understand English and to provide written informed consent and
             authorization for protected health information disclosure

        Exclusion Criteria:

          1. Concurrent skin pathology or recent history (within the past 5 years) of a chronic
             skin disease other than AD

          2. Use of phototherapy, including exposure to tanning beds, within 28 days of Study Drug
             application

          3. Taking systemic immunosuppressive drugs, biologicals, or corticosteroids therapy
             within (14 days), or topical immunosuppressive drugs or corticosteroid therapy (within
             7 days) of Study Drug application

          4. Females who are planning a pregnancy, who are pregnant, or who are breastfeeding

          5. Inability or unwillingness to discontinue current AD treatment(s)

          6. Inability or unwillingness to comply with study visit schedule and/or other study
             activities as required by the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nermina Nakas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinsys</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology and Cosmetic Surgery, Inc</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>November 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2011</results_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period for the study started 03Jun09. It was the responsibility of the PI for advertisement and recruitment of the study.</recruitment_details>
      <pre_assignment_details>There was a seven day run-in-period in which subjects self-applied the Vehicle control twice daily.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle</title>
          <description>once daily</description>
        </group>
        <group group_id="P2">
          <title>TS-022 0.005%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="P3">
          <title>TS-022 0.010%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="P4">
          <title>TS-022 0.020%</title>
          <description>lotion/once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle</title>
          <description>once daily</description>
        </group>
        <group group_id="B2">
          <title>TS-022 0.005%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="B3">
          <title>TS-022 0.010%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="B4">
          <title>TS-022 0.020%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="13.53"/>
                    <measurement group_id="B2" value="38.0" spread="11.63"/>
                    <measurement group_id="B3" value="35.1" spread="13.78"/>
                    <measurement group_id="B4" value="39.0" spread="13.89"/>
                    <measurement group_id="B5" value="36.4" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pruritis Visual Analog Scale (VAS)</title>
        <description>Patient reported outcome of pruritis measurement (0-100 mm/min-max)on a change in visual analog scale</description>
        <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
        <population>Intent To Treat (ITT) analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pruritis Visual Analog Scale (VAS)</title>
          <description>Patient reported outcome of pruritis measurement (0-100 mm/min-max)on a change in visual analog scale</description>
          <population>Intent To Treat (ITT) analysis</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="14.09"/>
                    <measurement group_id="O2" value="-15.5" spread="18.38"/>
                    <measurement group_id="O3" value="-13.9" spread="21.11"/>
                    <measurement group_id="O4" value="-6.2" spread="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of TS-022 Topical Lotion as Measured by Participants Who Demonstrated Adverse Events</title>
        <description>Safety assessment of all subjects who received investigational product. Outcome measure is number of subjects with an adverse event. Measures of adverse events in participants included vital signs, laboratory findings, physical exams, electrocardiograms</description>
        <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
        <population>total number of subjects who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of TS-022 Topical Lotion as Measured by Participants Who Demonstrated Adverse Events</title>
          <description>Safety assessment of all subjects who received investigational product. Outcome measure is number of subjects with an adverse event. Measures of adverse events in participants included vital signs, laboratory findings, physical exams, electrocardiograms</description>
          <population>total number of subjects who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Global Assessment (IGA) Based on a Dermatologist's Evalution of the Change in Subject's Score of Target Treatment Areas</title>
        <description>investigator assessment of disease status rated on 0-5 scale (0 = clear to 5 = very severe) based on a change in score from baseline to Study Day 36 (Visit 7)</description>
        <time_frame>baseline through Study Day 36 (Visit 7)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Assessment (IGA) Based on a Dermatologist's Evalution of the Change in Subject's Score of Target Treatment Areas</title>
          <description>investigator assessment of disease status rated on 0-5 scale (0 = clear to 5 = very severe) based on a change in score from baseline to Study Day 36 (Visit 7)</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-0.9" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.8" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-0.8" upper_limit="-0.2"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-0.8" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Five Point Pruritus Scale for Self-Assessment of Target Treatment Area Based on a Change in Score</title>
        <description>self-assessment using a five point scale of pruritus state based on a change in scale from none (0) to very severe (4), interfering with daily or sleep activities. Subjects will complete the Five-Point Pruritus Scale once at Screening (Visit 1), then twice daily beginning at baseline, which occurs on the morning of Study Day -7 (Visit 2), through Study Day 36 (Visit 7)</description>
        <time_frame>Baseline, which is Day -7 (Visit 2), through Day 36 (Visit 7)</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Five Point Pruritus Scale for Self-Assessment of Target Treatment Area Based on a Change in Score</title>
          <description>self-assessment using a five point scale of pruritus state based on a change in scale from none (0) to very severe (4), interfering with daily or sleep activities. Subjects will complete the Five-Point Pruritus Scale once at Screening (Visit 1), then twice daily beginning at baseline, which occurs on the morning of Study Day -7 (Visit 2), through Study Day 36 (Visit 7)</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.7" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.6" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-0.9" upper_limit="-0.3"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-0.5" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eczema Area and Severity Index (EASI) Based on a Change in Score of Eruption in Proportionate Body Surface Areas</title>
        <description>The head and neck [10%], trunk [30%], upper extremities [20%] and lower extremities [40%] were assessed separately for erythema (E), infiltration/papulation (I), excoriation (Ex) and lichenification (L) represented by a numeric coded value of (0, No eruption) to (6, 90% - 100% eruption). One score given to each part of the body on a scale from 1-6 based on the four attributes (E, I, Ex, L) and then a proportional average is taken to get a total score of 1-6.</description>
        <time_frame>baseline through Study Day 36 (Visit 7)</time_frame>
        <population>ITT analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Eczema Area and Severity Index (EASI) Based on a Change in Score of Eruption in Proportionate Body Surface Areas</title>
          <description>The head and neck [10%], trunk [30%], upper extremities [20%] and lower extremities [40%] were assessed separately for erythema (E), infiltration/papulation (I), excoriation (Ex) and lichenification (L) represented by a numeric coded value of (0, No eruption) to (6, 90% - 100% eruption). One score given to each part of the body on a scale from 1-6 based on the four attributes (E, I, Ex, L) and then a proportional average is taken to get a total score of 1-6.</description>
          <population>ITT analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="4.75"/>
                    <measurement group_id="O2" value="-2.1" spread="5.09"/>
                    <measurement group_id="O3" value="-2.7" spread="3.87"/>
                    <measurement group_id="O4" value="-2.3" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skindex-29 Questionnaire to Measure the Subject’s Overall Quality of Life Based on Activities of Daily Living That Affect Change in Emotion (10 to 50 Points), Symptoms (7 to 35 Points) and Functioning (12 to 60 Points) to Skin Over One Week Period.</title>
        <description>Assessment of subject's activities of daily living using the SKINDEX-29 questionnaire to measure the subject’s overall quality of life based on a change in scale from baseline. The SKINDEX scoring scale has a range of 29-145. The smaller the number the better the patient feels. The results are the difference of the SKINDEX scoring scale at treatment discharge (day 22) minus baseline (day-7). Hence the results should be negative, as the patient's emotion, symptoms and functioning of the skin should feel better at treatment discharge as opposed to baseline.</description>
        <time_frame>Study Day -7 through Study Day 22</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022 0.005%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O3">
            <title>TS-022 0.010%</title>
            <description>lotion/once daily</description>
          </group>
          <group group_id="O4">
            <title>TS-022 0.020%</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Skindex-29 Questionnaire to Measure the Subject’s Overall Quality of Life Based on Activities of Daily Living That Affect Change in Emotion (10 to 50 Points), Symptoms (7 to 35 Points) and Functioning (12 to 60 Points) to Skin Over One Week Period.</title>
          <description>Assessment of subject's activities of daily living using the SKINDEX-29 questionnaire to measure the subject’s overall quality of life based on a change in scale from baseline. The SKINDEX scoring scale has a range of 29-145. The smaller the number the better the patient feels. The results are the difference of the SKINDEX scoring scale at treatment discharge (day 22) minus baseline (day-7). Hence the results should be negative, as the patient's emotion, symptoms and functioning of the skin should feel better at treatment discharge as opposed to baseline.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="11.61"/>
                    <measurement group_id="O2" value="-12.1" spread="14.79"/>
                    <measurement group_id="O3" value="-12.3" spread="17.56"/>
                    <measurement group_id="O4" value="-4.1" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Measurable Pruritis Based on a Visual Horizontal Analog Scale</title>
        <description>Pruritis Visual Analog Scale (VAS) based on patient reported outcome of pruritis measurement on a VAS indicating the amount of pruritus (itchiness) experienced from the time of last dose application through the time just before current dose application. Change in pruritus is assessed twice daily beginning at baseline, Study Day -7 (Visit 2), through Study Day 36 (Visit 7). Subjects determine measurable pruritis using a visual horizontal analog scale ranging from &quot;No Itch&quot;, even the slightest itch or &quot;Slight Itch&quot;, to &quot;Worst Itch Imaginable&quot; to denote the increase in severity of itching.</description>
        <time_frame>Baseline through Study Day 36 (Visit 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>once daily</description>
          </group>
          <group group_id="O2">
            <title>TS-022</title>
            <description>lotion/once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Measurable Pruritis Based on a Visual Horizontal Analog Scale</title>
          <description>Pruritis Visual Analog Scale (VAS) based on patient reported outcome of pruritis measurement on a VAS indicating the amount of pruritus (itchiness) experienced from the time of last dose application through the time just before current dose application. Change in pruritus is assessed twice daily beginning at baseline, Study Day -7 (Visit 2), through Study Day 36 (Visit 7). Subjects determine measurable pruritis using a visual horizontal analog scale ranging from &quot;No Itch&quot;, even the slightest itch or &quot;Slight Itch&quot;, to &quot;Worst Itch Imaginable&quot; to denote the increase in severity of itching.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="12.4" upper_limit="14.09"/>
                    <measurement group_id="O2" value="78" lower_limit="15.5" upper_limit="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety and tolerability were assessed daily starting at Study Day -7 (Visit 2) through Study Day 52 (End of Study)</time_frame>
      <desc>Safety variables for evaluation included:
adverse events (AEs)
clinical laboratory assessments (blood chemistry, hematology, and urinalysis)
vital signs
physical examinations
electrocardiograms
pregnancy testing for females of child-bearing potential at specified times throughout the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>once daily</description>
        </group>
        <group group_id="E2">
          <title>TS-022 0.005%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="E3">
          <title>TS-022 0.010%</title>
          <description>lotion/once daily</description>
        </group>
        <group group_id="E4">
          <title>TS-022 0.020%</title>
          <description>lotion/once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (11.0)">Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.0)">Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (11.0)">Uppper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slower than expected enrollment and a higher than expected screen failure rate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fred Henry MS, MPH,</name_or_title>
      <organization>Taisho Pharmaceutical R&amp;D Inc.</organization>
      <phone>973-898-6200</phone>
      <email>F-Henry@taihso-rd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

